IMM2520 / ImmuneOnco Biopharma - LARVOL DELTA

IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy. (PubMed, Heliyon) - "In mouse transplantation models, compared with the first-generation CD47/PD-L1 BsAb (IMM2505), IMM2520 exhibited stronger and dose-dependent antitumor activity. These findings imply that IMM2520 may offer a novel therapeutic alternative for cancer patients."

Journal • Oncology • Transplantation • CD47 • SIRPA

A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor (ESMO 2024) - P1 | "IMM2520 showed tolerance at the evaluated doses and preliminary anti-tumor activity in advanced solid tumor, especially for SCLC. The dose escalation is ongoing."

Clinical • IO biomarker • Metastases • P1 data • Cervical Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • PD-L1 • SIRPA

'New Stock Performance' Immune Onco (01541.HK) opened 14% higher at 21.2 yuan [Google translation] (Yahoo Finance) - "It is expected that the net proceeds raised will be approximately 235 million yuan, of which approximately 40% and 28% will be used for the core product IMM01 respectively., as well as ongoing and planned clinical trials, preparation for registration applications and planned commercial launch of core products IMM0306, IMM2902 and IMM2520; approximately 10% will be used for planned clinical trials of IMM47 (CD24 monoclonal antibody)."

Commercial • Oncology

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Preclinical development of a novel bispecific mAb-Trap fusion protein, IMM2520, targeting both PD-L1 and CD47 as cancer immunotherapy (AACR 2023) - "Interestingly, IMM2520 demonstrated a potent and significantly higher anti-tumor activities than IMM01 (a SIRPα-Fc fusion protein) and IMM2505 (also a CD47XPD-L1 mAb-Trap, but the variable region sequence of this PD-L1 antibody is identical to atezolizumab). In another in vivo efficacy study with MC38-hCD47/hPD-L1 colon cancer model, IMM2520 demonstrated a significant anti-tumor activity in a dose-dependent manner at doses between 2 mg/kg to 20 mg/kg. Given its potent preclinical anti-tumor activity as well as the favorable safety profile, IMM2520 may serve as a potent immunotherapy for multiple cancer types by targeting PD-L1 and CD47 on tumor cells."

Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CTCs • SIRPA

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Metastases • New P1 trial • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

The Synergistic Anti-Tumor Activities of CD47-Based Bispecific Molecules in Experimental Solid Tumors Are Dependent on Interaction of Tumor Targets (PEGS 2022) - "Surprisingly, while four bispecific mAb-Traps (IMM0306: CD47/CD20, IMM2902: CD47/Her2, IMM2520: CD47/PD-L1, IMM5601: CD47/CD38) revealed potent synergistic anti-tumor activities, two (IMM0404: CD47/EGFR, IMM3202: CD47/VEGFR2), did not generate such effect. In those two mAb-Trap molecules, linkage of CD47 ligand trap (SIRPa decoy) onto EGFR antibody or VEGFR2 antibody actually reduced therapeutic effects. Thus the synergistic anti-tumor activities of CD47-based bi-specific molecules in experimental solid tumors are dependent on interaction of tumor targets; structural design and target selection deserve careful consideration."

Oncology • Solid Tumor • CD20 • HER-2 • PD-L1 • SIRPA